Clarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings EBIT

EBIT (Earnings Before Interest and Taxes) analysis for CRXT.

Quarterly EBIT

-$8.67M

↑ 34.48% YoY

As of Jun 30, 2022

Annual EBIT (TTM)

-$33.06M

↓ 50.35% YoY

Trailing 12 months ending Jun 30, 2022

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin